Ocular Therapeutix announced that it has strengthened its clinical development organization with the appointment of Nadia K. Waheed, MD, MPH, as Chief Medical Officer, CMO; Peter Kaiser, MD as Chief Development Officer, CDO; Andrea Gibson, Ph.D., as Vice President, Medical Collaborations; and Namrata Saroj, OD, as Development Strategy Consultant. Dr. Waheed’s appointment will be effective as of May 20, 2024. Jeffrey Heier, MD, will continue in his role as Chief Scientific Officer.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCUL:
- Ocular Therapeutix appoints Dugel as President, CEO
- Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics
- Ocular Therapeutix reports inducement grants under Nasdaq listing rule
- Ocular Therapeutix announces Phase 2 PAXTRAVA glaucoma data
- Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting
